These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 39286522)

  • 21. SUMO1 Modification of Tau in Progressive Supranuclear Palsy.
    Takamura H; Nakayama Y; Ito H; Katayama T; Fraser PE; Matsuzaki S
    Mol Neurobiol; 2022 Jul; 59(7):4419-4435. PubMed ID: 35567706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SUMOylation of the ubiquitin ligase IDOL decreases LDL receptor levels and is reversed by SENP1.
    Wang JQ; Lin ZC; Li LL; Zhang SF; Li WH; Liu W; Song BL; Luo J
    J Biol Chem; 2021; 296():100032. PubMed ID: 33154164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases.
    Kotaja N; Karvonen U; Jänne OA; Palvimo JJ
    Mol Cell Biol; 2002 Jul; 22(14):5222-34. PubMed ID: 12077349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution and paralogue specificity of mammalian deSUMOylating enzymes.
    Kolli N; Mikolajczyk J; Drag M; Mukhopadhyay D; Moffatt N; Dasso M; Salvesen G; Wilkinson KD
    Biochem J; 2010 Sep; 430(2):335-44. PubMed ID: 20590526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SUMOylation and DeSUMOylation: Prospective therapeutic targets in cancer.
    Wu W; Huang C
    Life Sci; 2023 Nov; 332():122085. PubMed ID: 37722589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sentrin/SUMO specific proteases as novel tissue-selective modulators of vitamin D receptor-mediated signaling.
    Lee WP; Jena S; Doherty D; Ventakesh J; Schimdt J; Furmick J; Widener T; Lemau J; Jurutka PW; Thompson PD
    PLoS One; 2014; 9(2):e89506. PubMed ID: 24586832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.
    Schmidt D; Müller S
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2872-7. PubMed ID: 11867732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function.
    Cong L; Pakala SB; Ohshiro K; Li DQ; Kumar R
    J Biol Chem; 2011 Dec; 286(51):43793-43808. PubMed ID: 21965678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SENP1 and SENP2 regulate SUMOylation of amyloid precursor protein.
    Maruyama T; Abe Y; Niikura T
    Heliyon; 2018 Apr; 4(4):e00601. PubMed ID: 29862363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The allosteric effect of the upper half of SENP1 contributes to its substrate selectivity for SUMO1 over SUMO2.
    Shi Y; Yasen M; Wang Z; Du T; Ding Y; Li X; Chai Z; Jie C; Ju G; Ji M
    J Biomol Struct Dyn; 2023; 41(21):12372-12386. PubMed ID: 36656084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SUMO E3 ligases are expressed in the retina and regulate SUMOylation of the metabotropic glutamate receptor 8b.
    Dütting E; Schröder-Kress N; Sticht H; Enz R
    Biochem J; 2011 Apr; 435(2):365-71. PubMed ID: 21288202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Potential of Targeting the SUMO Pathway in Cancer.
    Kukkula A; Ojala VK; Mendez LM; Sistonen L; Elenius K; Sundvall M
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SUMO proteases as potential targets for cancer therapy.
    Bialik P; Woźniak K
    Postepy Hig Med Dosw (Online); 2017 Dec; 71(0):997-1004. PubMed ID: 29225200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
    Citro S; Chiocca S
    Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic Polymorphism of SUMO-Specific Cysteine Proteases - SENP1 and SENP2 in Breast Cancer.
    Mirecka A; Morawiec Z; Wozniak K
    Pathol Oncol Res; 2016 Oct; 22(4):817-23. PubMed ID: 27178176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The SUMO-specific protease SENP1 deSUMOylates p53 and regulates its activity.
    Chauhan KM; Chen Y; Chen Y; Liu AT; Sun XX; Dai MS
    J Cell Biochem; 2021 Feb; 122(2):189-197. PubMed ID: 32786121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arkadia/RNF111 is a SUMO-targeted ubiquitin ligase with preference for substrates marked with SUMO1-capped SUMO2/3 chain.
    Sriramachandran AM; Meyer-Teschendorf K; Pabst S; Ulrich HD; Gehring NH; Hofmann K; Praefcke GJK; Dohmen RJ
    Nat Commun; 2019 Aug; 10(1):3678. PubMed ID: 31417085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Role for Protein Inhibitor of Activated STAT 4 (PIAS4) in the Restriction of Herpes Simplex Virus 1 by the Cellular Intrinsic Antiviral Immune Response.
    Conn KL; Wasson P; McFarlane S; Tong L; Brown JR; Grant KG; Domingues P; Boutell C
    J Virol; 2016 May; 90(9):4807-4826. PubMed ID: 26937035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sumoylation of CoREST modulates its function as a transcriptional repressor.
    Muraoka A; Maeda A; Nakahara N; Yokota M; Nishida T; Maruyama T; Ohshima T
    Biochem Biophys Res Commun; 2008 Dec; 377(4):1031-5. PubMed ID: 18854179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates.
    Gocke CB; Yu H; Kang J
    J Biol Chem; 2005 Feb; 280(6):5004-12. PubMed ID: 15561718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.